Cargando…

Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study

Higher vascular disease burden increases the likelihood of developing dementia, including Alzheimer’s disease. Better understanding the association between vascular risk factors and Alzheimer’s disease pathology at the predementia stage is critical for developing effective strategies to delay cognit...

Descripción completa

Detalles Bibliográficos
Autores principales: van Arendonk, Joyce, Neitzel, Julia, Steketee, Rebecca M E, van Assema, Daniëlle M E, Vrooman, Henri A, Segbers, Marcel, Ikram, M Arfan, Vernooij, Meike W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825526/
https://www.ncbi.nlm.nih.gov/pubmed/36374264
http://dx.doi.org/10.1093/brain/awac354
_version_ 1784866651607400448
author van Arendonk, Joyce
Neitzel, Julia
Steketee, Rebecca M E
van Assema, Daniëlle M E
Vrooman, Henri A
Segbers, Marcel
Ikram, M Arfan
Vernooij, Meike W
author_facet van Arendonk, Joyce
Neitzel, Julia
Steketee, Rebecca M E
van Assema, Daniëlle M E
Vrooman, Henri A
Segbers, Marcel
Ikram, M Arfan
Vernooij, Meike W
author_sort van Arendonk, Joyce
collection PubMed
description Higher vascular disease burden increases the likelihood of developing dementia, including Alzheimer’s disease. Better understanding the association between vascular risk factors and Alzheimer’s disease pathology at the predementia stage is critical for developing effective strategies to delay cognitive decline. In this work, we estimated the impact of six vascular risk factors on the presence and severity of in vivo measured brain amyloid-beta (Aβ) plaques in participants from the population-based Rotterdam Study. Vascular risk factors (hypertension, hypercholesterolaemia, diabetes, obesity, physical inactivity and smoking) were assessed 13 (2004–2008) and 7 years (2009–2014) prior to (18)F-florbetaben PET (2018–2021) in 635 dementia-free participants. Vascular risk factors were associated with binary amyloid PET status or continuous PET readouts (standard uptake value ratios, SUVrs) using logistic and linear regression models, respectively, adjusted for age, sex, education, APOE4 risk allele count and time between vascular risk and PET assessment. Participants’ mean age at time of amyloid PET was 69 years (range: 60–90), 325 (51.2%) were women and 190 (29.9%) carried at least one APOE4 risk allele. The adjusted prevalence estimates of an amyloid-positive PET status markedly increased with age [12.8% (95% CI 11.6; 14) in 60–69 years versus 35% (36; 40.8) in 80–89 years age groups] and APOE4 allele count [9.7% (8.8; 10.6) in non-carriers versus 38.4% (36; 40.8) to 60.4% (54; 66.8) in carriers of one or two risk allele(s)]. Diabetes 7 years prior to PET assessment was associated with a higher risk of a positive amyloid status [odds ratio (95% CI) = 3.68 (1.76; 7.61), P < 0.001] and higher standard uptake value ratios, indicating more severe Aβ pathology [standardized beta = 0.40 (0.17; 0.64), P = 0.001]. Hypertension was associated with higher SUVr values in APOE4 carriers (mean SUVr difference of 0.09), but not in non-carriers (mean SUVr difference 0.02; P = 0.005). In contrast, hypercholesterolaemia was related to lower SUVr values in APOE4 carriers (mean SUVr difference −0.06), but not in non-carriers (mean SUVr difference 0.02). Obesity, physical inactivity and smoking were not related to amyloid PET measures. The current findings suggest a contribution of diabetes, hypertension and hypercholesterolaemia to the pathophysiology of Alzheimer’s disease in a general population of older non-demented adults. As these conditions respond well to lifestyle modification and drug treatment, further research should focus on the preventative effect of early risk management on the development of Alzheimer’s disease neuropathology.
format Online
Article
Text
id pubmed-9825526
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98255262023-01-10 Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study van Arendonk, Joyce Neitzel, Julia Steketee, Rebecca M E van Assema, Daniëlle M E Vrooman, Henri A Segbers, Marcel Ikram, M Arfan Vernooij, Meike W Brain Original Article Higher vascular disease burden increases the likelihood of developing dementia, including Alzheimer’s disease. Better understanding the association between vascular risk factors and Alzheimer’s disease pathology at the predementia stage is critical for developing effective strategies to delay cognitive decline. In this work, we estimated the impact of six vascular risk factors on the presence and severity of in vivo measured brain amyloid-beta (Aβ) plaques in participants from the population-based Rotterdam Study. Vascular risk factors (hypertension, hypercholesterolaemia, diabetes, obesity, physical inactivity and smoking) were assessed 13 (2004–2008) and 7 years (2009–2014) prior to (18)F-florbetaben PET (2018–2021) in 635 dementia-free participants. Vascular risk factors were associated with binary amyloid PET status or continuous PET readouts (standard uptake value ratios, SUVrs) using logistic and linear regression models, respectively, adjusted for age, sex, education, APOE4 risk allele count and time between vascular risk and PET assessment. Participants’ mean age at time of amyloid PET was 69 years (range: 60–90), 325 (51.2%) were women and 190 (29.9%) carried at least one APOE4 risk allele. The adjusted prevalence estimates of an amyloid-positive PET status markedly increased with age [12.8% (95% CI 11.6; 14) in 60–69 years versus 35% (36; 40.8) in 80–89 years age groups] and APOE4 allele count [9.7% (8.8; 10.6) in non-carriers versus 38.4% (36; 40.8) to 60.4% (54; 66.8) in carriers of one or two risk allele(s)]. Diabetes 7 years prior to PET assessment was associated with a higher risk of a positive amyloid status [odds ratio (95% CI) = 3.68 (1.76; 7.61), P < 0.001] and higher standard uptake value ratios, indicating more severe Aβ pathology [standardized beta = 0.40 (0.17; 0.64), P = 0.001]. Hypertension was associated with higher SUVr values in APOE4 carriers (mean SUVr difference of 0.09), but not in non-carriers (mean SUVr difference 0.02; P = 0.005). In contrast, hypercholesterolaemia was related to lower SUVr values in APOE4 carriers (mean SUVr difference −0.06), but not in non-carriers (mean SUVr difference 0.02). Obesity, physical inactivity and smoking were not related to amyloid PET measures. The current findings suggest a contribution of diabetes, hypertension and hypercholesterolaemia to the pathophysiology of Alzheimer’s disease in a general population of older non-demented adults. As these conditions respond well to lifestyle modification and drug treatment, further research should focus on the preventative effect of early risk management on the development of Alzheimer’s disease neuropathology. Oxford University Press 2022-11-12 /pmc/articles/PMC9825526/ /pubmed/36374264 http://dx.doi.org/10.1093/brain/awac354 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
van Arendonk, Joyce
Neitzel, Julia
Steketee, Rebecca M E
van Assema, Daniëlle M E
Vrooman, Henri A
Segbers, Marcel
Ikram, M Arfan
Vernooij, Meike W
Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
title Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
title_full Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
title_fullStr Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
title_full_unstemmed Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
title_short Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
title_sort diabetes and hypertension are related to amyloid-beta burden in the population-based rotterdam study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825526/
https://www.ncbi.nlm.nih.gov/pubmed/36374264
http://dx.doi.org/10.1093/brain/awac354
work_keys_str_mv AT vanarendonkjoyce diabetesandhypertensionarerelatedtoamyloidbetaburdeninthepopulationbasedrotterdamstudy
AT neitzeljulia diabetesandhypertensionarerelatedtoamyloidbetaburdeninthepopulationbasedrotterdamstudy
AT steketeerebeccame diabetesandhypertensionarerelatedtoamyloidbetaburdeninthepopulationbasedrotterdamstudy
AT vanassemadanielleme diabetesandhypertensionarerelatedtoamyloidbetaburdeninthepopulationbasedrotterdamstudy
AT vroomanhenria diabetesandhypertensionarerelatedtoamyloidbetaburdeninthepopulationbasedrotterdamstudy
AT segbersmarcel diabetesandhypertensionarerelatedtoamyloidbetaburdeninthepopulationbasedrotterdamstudy
AT ikrammarfan diabetesandhypertensionarerelatedtoamyloidbetaburdeninthepopulationbasedrotterdamstudy
AT vernooijmeikew diabetesandhypertensionarerelatedtoamyloidbetaburdeninthepopulationbasedrotterdamstudy